Danaher Corporation, founded in 1969 and headquartered in Washington, D.C., is a globally recognized science and technology company dedicated to enhancing the quality of life through innovative solutions. The company operates through two segments: Life Sciences and Diagnostics, offering products such as analytical instruments, biotechnology tools, and medical devices that support research and healthcare initiatives.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| DHR 2.10% 2026-09-30 EURDanaher Corp. | United States | 2026-09-30 | 2.100 | 2.28 |
| DHR 2.50% 2030-03-30 EURDanaher Corp. | United States | 2030-03-30 | 2.500 | 2.77 |
| DHR 2.60% 2050-10-01 USDDanaher Corp. | United States | 2050-10-01 | 2.600 | 5.42 |
| DHR 2.80% 2051-12-10 USDDanaher Corp. | United States | 2051-12-10 | 2.800 | 5.40 |
| DHR 3.35% 2025-09-15 USDDanaher Corp. | United States | 2025-09-15 | 3.350 | 0.00 |
| DHR 4.38% 2045-09-15 USDDanaher Corp. | United States | 2045-09-15 | 4.375 | 5.33 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Danaher has actively participated in the bond market since the early 2000s, leveraging bond issuances to finance acquisitions and support growth strategies. Notable issuances include a $1 billion bond in 2016 that facilitated the purchase of GE Biotech and a subsequent $500 million offering in 2020 with competitive yields compared to industry peers. Currently, Danaher’s bonds demonstrate attractive features, including a favorable pricing structure. Recent reports indicate that the company's credit ratings remain strong, contributing to robust investor interest and confidence in its financial stability.